Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.74 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 9/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14857496 | 0.88 | FFAR1 (0.78) | FFAR1AAK1LPLLIPGDGAT1 | |
| SCHEMBL16112599 | 0.85 | FFAR1 (0.66) | FFAR1AAK1LPLLIPGDGAT1 | |
| SCHEMBL23414888 | 0.85 | FFAR1 (0.74) | FFAR1AAK1LPLLIPGDGAT1 | |
| SCHEMBL9281333 | 0.85 | FFAR1 (0.74) | FFAR1AAK1LPLLIPGDGAT1 | |
| SCHEMBL304019 | 0.85 | FFAR1 (1.00) | FFAR1LPLLIPGDGAT1F11 | |
| SCHEMBL4128208 | 0.83 | FFAR1 (0.71) | FFAR1AAK1LPLLIPGDGAT1 | |
| SCHEMBL9277388 | 0.82 | FFAR1 (0.74) | FFAR1AAK1LPLLIPGDGAT1 | |
| SCHEMBL20599451 | 0.82 | FFAR1 (0.70) | FFAR1AAK1LPLLIPGDGAT1 | |
| SCHEMBL15376959 | 0.82 | FFAR1 (0.70) | FFAR1AAK1LPLLIPGDGAT1 | |
| SCHEMBL2581046 | 0.82 | FFAR1 (0.70) | FFAR1AAK1LPLLIPGDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023097195-A1 | THERAPEUTIC INDAZOLE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20230121440-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2023-04-20 | — | — | US | disclosed |
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | E-THERAPEUTICS PLC (GB) | 2021-08-05 | — | — | US | disclosed |
| WO-2019173761-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-09-12 | — | — | WO | disclosed |
| EP-3380469-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2018-10-03 | — | — | EP | disclosed |
| EP-3365335-A1 | 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | Array Biopharma, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017091661-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | STROVEL JEFFREY WILLIAM (US) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017070708-A1 | 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| EP-2961410-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K RELATED DISORDERS | Incyte Holdings Corporation (US) | 2016-01-06 | — | — | EP | disclosed |
| WO-2014134426-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS | INCYTE CORPORATION (US) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014111871-A1 | 4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-07-24 | — | — | WO | disclosed |
| EP-2751109-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Corporation (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033569-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121440-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | FFAR1 3228/4885AAK1 451/4885LPL 3855/4885 |
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | TPH1, KYNU, TPH2 | FFAR1 1945/4885AAK1 1426/4885LPL 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.